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Aldo-Keto Reductase 1C3 Is Expressed in
Differentiated Human Epidermis, Affects
Keratinocyte Differentiation, and Is Upregulated in
Atopic Dermatitis
Alon Mantel1,2, Amanda B. Carpenter-Mendini1, JoAnne B. VanBuskirk1, Anna De Benedetto1, Lisa A. Beck1
and Alice P. Pentland1
Aldo-keto reductase 1C3 (AKR1C3) has been shown to mediate the metabolism of sex hormones and
prostaglandin D2 (PGD2), a lipid mediator that promotes skin inflammation in atopic dermatitis (AD). As both
have a role in skin function and pathology, we first sought to investigate the expression pattern of AKR1C3 in
normal human epidermis. Immunofluorescence revealed a strong expression of AKR1C3 in the differentiated
suprabasal layers compared with the basal layer. Western blot analysis and quantitative PCR confirmed that
AKR1C3 expression was also upregulated in differentiation-induced primary human keratinocytes (PHKs). To
investigate the functional role of AKR1C3 during PHK differentiation, its expression and activity (measured as
PGD2 reduction to 9a,11b-PGF2 by ELISA) were impaired by small interfering RNA or 20-hydroxyflavanone,
respectively. Cytokeratin 10 (K10) and loricrin expression were then examined by western blot analysis, thus
revealing altered expression of these differentiation markers. Finally, following an observation that the AD-
associated mediator, PGD2, upregulated AKR1C3 expression in PHKs, we used immunofluorescence to examine
AKR1C3 expression in AD and psoriasis lesions. AKR1C3 was found to be upregulated in AD but not in psoriasis
lesions compared with non-lesional skin. Our work demonstrates a function for AKR1C3 in differentiation-
associated gene regulation and also suggests a role in supporting inflammation in AD.
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INTRODUCTION
Human skin is considered a steroidogenic organ because it
locally synthesizes and metabolizes various steroid hormones
and expresses their corresponding receptors (Thiboutot et al.,
2003; Kanda and Watanabe, 2005; Zouboulis et al., 2007).
Prostaglandins (PGs), a large family of arachidonic acid–
derived lipid mediators, have also been shown to have a role
in skin function and pathology, including keratinocyte
proliferation and differentiation, skin cancer, and allergic
inflammation (Konger et al., 2009; Chun et al., 2010; He
et al., 2010; Surh et al., 2011). As specific enzymes
contribute to the regulation of local concentrations of steroid
hormones and PGs in the skin, their distribution and activity
may indirectly affect skin function.
Several aldo-keto reductase 1C (AKR1C) enzymes have
been shown to synthesize or metabolize steroid hormones
and/or PGs (Penning et al., 2003, 2006), and recent work has
also characterized their expression in cultured human
keratinocytes and suggested a possible role for them in
keratinocyte survival (Marin et al., 2009). AKR1C enzymes
are part of a larger AKR superfamily that uses NAD(P)(H) as a
cofactor to mediate the enzymatic reduction of aldehyde and
ketone groups of various substrates to their corresponding
alcohols (Jez et al., 1997a, b). In humans, there are four
AKR1C enzymes, AKR1C1–AKR1C4, that share about 86%
amino-acid sequence identity, yet vary in their substrate-
binding specificities (Penning et al., 2000). AKR1C1 and
AKR1C2 primarily convert specific potent steroid hormones
into their less potent forms (Rizner et al., 2003, 2006). In
contrast, AKR1C3, also known as type 5 17b-hydroxysteroid
dehydrogenase (17b-HSD; Lin et al., 1997) and prostaglandin
F synthase (Matsuura et al., 1998; Suzuki-Yamamoto et al.,
1999), converts the weak androgen D4-androstene-3,17-dione
to testosterone (potent androgen) and the weak estrogen
estrone to its potent form, 17b-estradiol (Lin et al., 1997).
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Unlike other AKR1C members, AKR1C3 can also synthesize
PGF2a from the cyclooxygenase product PGH2 and mediate
one of its most favorable catalytic activities, the reduction
of prostaglandin D2 (PGD2) to 9a,11b-PGF2 (Lin et al., 1997;
Matsuura et al., 1998; Suzuki-Yamamoto et al., 1999;
Penning et al., 2000, 2006; Byrns et al., 2010).
Human skin is a major site for synthesis of PGD2,
where it is synthesized primarily by immune cells such
as macrophages, Langerhans cells, and mast cells (Morrow
et al., 1992; Shimura et al., 2010). In skin, PGD2 is
mostly investigated in the context of allergic responses,
particularly in supporting inflammation in atopic dermatitis
(AD) lesions (Barr et al., 1988; Satoh et al., 2006; Shimura
et al., 2010).
The involvement of AKR1C3 in both PG and steroid
hormone metabolism clearly situates this enzyme at the
intersection of several very important physiological and
pathological signaling pathways in the skin. We therefore
characterized its expression pattern in normal human
epidermis and in the epidermis from AD and psoriasis
patients, as well as examined its regulation and function in
cultured primary human keratinocytes (PHKs).
RESULTS
AKR1C3 is expressed in differentiated human epidermis and
colocalizes with cytokeratin 10 (K10)
To define the expression pattern of AKR1C3 within the
human epidermis, skin was evaluated by immunofluores-
cence using AKR1C3 antibody alone or in combination with
layer-specific epidermal markers. AKR1C3 staining intensity
varied within the epidermal layers, with the weakest intensity
observed in the basal layer and stronger expression noted
in suprabasal layers, especially in the stratum spinosum
(Figure 1a). On average, AKR1C3 expression was 2.3±0.07-
fold higher in the suprabasal layers compared with the basal
layer as determined by ImageJ analysis (Figure 1b). In double
immunolabeling experiments (Figure 1c) using the basal layer
marker cytokeratin 5 (K5, green) or the early differentiation
marker K10 (green) together with AKR1C3 (red), AKR1C3
colocalized with K10 (yellow), especially in the stratum
spinosum, but did not appear to colocalize with K5 in the
basal layer.
AKR1C3 protein and mRNA are upregulated in
calcium-induced PHK differentiation
As AKR1C3 showed stronger expression in differentiated
epidermis, its regulation in response to calcium-induced
differentiation was evaluated in PHKs. Cultures treated with
1.8mM calcium chloride or with equal volume of phosphate-
buffered saline were harvested at 24, 48, and 72 hours post
treatment, and AKR1C3 protein and mRNA levels were
assessed using western blot analysis or quantitative reverse
transcription-PCR. Western blot analysis demonstrated a
time-dependent upregulation of AKR1C3 protein in high
calcium-treated cells, and was similar to the expected
upregulation trend of the early differentiation marker K10
Suprabasal
Basal layer
AKR1C3 DAPI
AKR1C3
AKR1C3AKR1C3
AKR1C3DAPI K10
K5 K5
DAPI
DAPIDAPI
K10 DAPI
DAPI
mlgG
AK
R
1C
3 
ex
pr
es
sio
n
(av
e
ra
ge
 p
ixe
l i
nt
en
si
ty
) 40,000
30,000
20,000
10,000
0
Basal Suprabasal
*
Figure 1. Aldo-keto reductase 1C3 (AKR1C3) is expressed in differentiated human epidermis and colocalizes with cytokeratin 10 (K10). (a) AKR1C3
expression patterns were evaluated in normal human epidermis by immunofluorescence staining using AKR1C3 antibody and (b) quantified with ImageJ.
Data are shown as the mean±SEM pixel intensity after background subtraction (n¼3, *Po0.05). (c) Normal human skin was subjected to double-label
immunofluorescence staining using AKR1C3 (red) and cytokeratin 10 (K10, green) or cytokeratin 5 (K5, green) antibodies. Labeling of each protein is shown
separately in the middle and left panels. Yellow color in the merged pictures (right panels) suggests a colocalization of the two proteins.
Bar¼30 mm, n¼3. DAPI, 40-6-diamidino-2-phenylindole.
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(Figure 2a). A 30- to 40-fold increase in AKR1C3 mRNA
was also observed in high calcium-treated cells (Figure 2c).
Next, cells were treated with the indicated calcium doses
and harvested 48 hours post treatment. Western blot
analysis revealed a dose-dependent upregulation of AKR1C3
protein, which again correlated with K10 expression
(Figure 2b). A dose-dependent upregulation of AKR1C3
mRNA of up to 28±20.5-fold over control was also noted
(Figure 2d).
AKR1C3 small interfering RNA (siRNA) specifically attenuates
calcium-induced AKR1C3 expression
To investigate AKR1C3 function in keratinocytes, the effec-
tiveness and specificity of an AKR1C3 siRNA construct
were evaluated. PHKs were transiently transfected with either
10 nM of AKR1C3 or nonspecific siRNA, allowed to differ-
entiate in 1.8mM calcium for 48 hours, and then harvested for
protein and mRNA analysis. AKR1C3 protein expression,
determined by western blot analysis, was markedly reduced
in AKR1C3 siRNA–treated cells compared with controls,
demonstrating the effectiveness of this treatment
(Figure 3a). AKR1C2 is a closely related family member of
AKR1C3, which shares about 86% amino-acid sequence
homology (Jez et al., 1997a). To test the efficiency and
specificity of the AKR1C3 siRNA construct, mRNA samples
from AKR1C3 or control siRNA–treated cells were
collected, and the relative change in AKR1C3 and AKR1C2,
compared with controls, was determined using reverse
transcription-PCR (Figure 3b). Although AKR1C3 mRNA
levels in AKR1C3 siRNA–treated cells were reduced
46.6±19.1-fold over control siRNA, the reduction of
AKR1C2 was not significant.
AKR1C3 siRNA and 20-hydroxyflavanone (2HFN) attenuated
AKR1C3 enzymatic activity (measured as PGD2 reduction to
9a,11b-PGF2) in PHKs
We next evaluated the effects of AKR1C3 protein reduction
by siRNA or the specific AKR1C3 inhibitor 2HFN (Skarydova
et al., 2009) on AKR1C3 enzymatic activity in PHKs. Cells
were transfected with 10 nM AKR1C3 or control siRNA and
induced to differentiate for 48 hours by 1.8mM calcium.
Conversion of exogenously added PGD2 to 9a,11b-PGF2 was
then assessed in the supernatants by ELISA. 9a,11b-PGF2
levels in supernatants from AKR1C3 siRNA–treated cells were
lower at all time points (14.7±2.4 fold on average) compared
with control cells (Figure 3c). Next, keratinocytes were
induced to differentiate for 48 hours, and 9a,11b-PGF2
generation from PGD2 in the presence of the indicated doses
of 2HFN was assessed in supernatants 2 hours post treatment.
The presence of 2HFN dose-dependently attenuated 9a,11b-
PGF2 generation. The maximal 2HFN concentration tested
(5 mM) reduced 9a,11b-PGF2 levels to 15.4±2% of that
measured in vehicle-treated cells (Figure 3d). These data
confirmed that both AKR1C3 siRNA and 2HFN treatments
resulted in the inhibition of this specific activity of AKR1C3
in PHKs.
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Figure 2. Aldo-keto reductase 1C3 (AKR1C3) protein and mRNA are
upregulated in response to calcium-induced primary human keratinocyte
(PHK) differentiation in a time- and dose-dependent manner. (a) Western
blot analysis demonstrating the regulation of AKR1C3 by PHK cultured
under 1.8 or 0.03mM calcium conditions and harvested at intervals, or
(b) by cells treated with the indicated dose of calcium and harvested
48hours post treatment (representative results of three separate experiments
is shown). (c, d) Reverse transcription-PCR analysis demonstrating the
regulation of AKR1C3 mRNA by cells treated under the same conditions
described in a or b, respectively. Data are expressed as means±SEM fold
change over the baseline (n¼ 3, *Po0.015).
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Figure 3. Aldo-keto reductase 1C3 (AKR1C3) small interfering RNA (siRNA)
and 20-hydroxyflavanone (2HFN) attenuate AKR1C3 enzymatic activity.
(a) Primary human keratinocytes (PHKs) transfected with 10 nM of AKR1C3
or nonspecific siRNA (Con siRNA) were allowed to differentiate for
48 hours and AKR1C3 protein was evaluated by western blot (n¼ 3).
(b) To examine AKR1C3 siRNA specificity, cells were treated as described
in a, mRNA was extracted, and the transcription of AKR1C3 and AKR1C2
was evaluated by reverse transcription-PCR (means±SEM, n¼4, *Po0.05).
(c) PHKs were treated with AKR1C3 or control siRNA, allowed to differentiate
for 48 hours, and AKR1C3 enzymatic activity was evaluated at intervals by
assessing 9a,11b-PGF2 in supernatants using ELISA (means±SEM, n¼4,
*Po0.05, **Po0.01). (d) 2HFN dose dependently reduced AKR1C3
activity in PHKs, as determined by ELISA quantification of 9a,11b-PGF2
levels in supernatants, 2 hours post treatment (n¼ 4, *Po0.05,
**Po0.01).
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AKR1C3 siRNA and 2HFN treatment altered K10 and loricrin
regulation during calcium-induced PHK differentiation
We postulated that AKR1C3 upregulation has a role in
differentiation-associated gene regulation during calcium-
induced differentiation. To test this, AKR1C3 protein expression
or enzymatic activity was attenuated during differentiation,
and K10 and loricrin expressions were evaluated at intervals
by western blot analysis (Figure 4). PHKs were transfected
with AKR1C3 or nonspecific siRNA and induced to differ-
entiate for the indicated times (Figure 4a). AKR1C3 siRNA
treatment effectively reduced AKR1C3 protein expression at
all tested time points, which also resulted in a marked
reduction in K10 expression. Interestingly, in contrast to K10
reduction, AKR1C3 siRNA transfectants demonstrated an
earlier and stronger expression of loricrin. Furthermore, cells
that were induced to differentiate by calcium in the presence
of 1 mM of the AKR1C3-specific inhibitor 2HFN also demon-
strated the same abnormal expression pattern of K10 and
loricrin (Figure 4b).
AKR1C3 is upregulated in response to PGD2 in PHKs
As our data suggested that PHKs use AKR1C3 to metabolize
PGD2, we sought to further evaluate the effect of PGD2 on
AKR1C3 expression. PHKs were incubated in various
concentrations of PGD2 (under low calcium conditions) for
24 hours and then harvested for analysis of AKR1C3
protein and mRNA. A dose-dependent upregulation of
AKR1C3 in response to PGD2 was observed at the protein
level (Figure 5a), determined by western blot analysis, and at
the transcription level (Figure 5b), determined by reverse
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Figure 4. Treatment with aldo-keto reductase 1C3 (AKR1C3) siRNA
or the AKR1C3 inhibitor 20-hydroxyflavanone (2HFN) results in abnormal
cytokeratin 10 (K10) and loricrin regulation during primary human
keratinocytes (PHK) differentiation. (a) PHKs were treated with 10 nM of
control or AKR1C3 siRNA, or with (b) 1 mM 2HFN or an equal volume of
DMSO (con). Cells from both experiments were induced to differentiate
with 1.8mM calcium for the indicated durations, and the expression
of K10 and loricrin was evaluated by western blot analysis. A representative
blot of three separate experiments is shown. K10 and loricrin are shown
on two separate blots in panel b.
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Figure 5. Aldo-keto reductase 1C3 (AKR1C3) is upregulated in atopic dermatitis (AD) lesions and in primary human keratinocytes (PHKs) treated
with prostaglandin D2 (PGD2). (a) Dose-dependent upregulation of AKR1C3 protein and (b) mRNA by PHKs treated with various doses of PGD2 and
harvested after 24 hours, determined by western blot analysis (n¼ 3) and reverse transcription-PCR (means±SEM, n¼ 3, *Po0.01), respectively. (c) PHKs
were treated with 5 mM of the indicated prostaglandin for 24 hours, and the regulation of AKR1C3 was assessed by western blot analysis (n¼ 3).
(d) Immunofluorescence staining showing the relative expression of AKR1C3 in the epidermis of AD (n¼ 4) psoriasis (Pso, n¼ 3) and normal skin (n¼ 4).
One representative case is shown; images obtained at  10 magnification. (e) ImageJ analysis of AKR1C3 staining intensity. Data are presented as the
mean±SEM of two separate experiments in which four normal skin samples, four AD, and three psoriasis cases were evaluated. L, lesion; NL, non-lesion.
*Po0.001, **P¼ 0.012.
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transcription-PCR. AKR1C3 mRNA levels were increased
by up to 58.5±18.1-fold in cells treated with 5 mM PGD2.
To evaluate the specificity of this response, cells were
incubated in the presence of 5 mM of either PGD2, PGE2, or
9a,11b-PGF2, and the expression of AKR1C3 was
evaluated by western blot analysis (Figure 5c). The expected
upregulation of AKR1C3 was observed in PGD2-treated
cells, but was absent in the other tested conditions,
suggesting that this response was specific to PGD2. In
addition, incubation of PHKs in the presence of 5 mM of D4-
androstene-3,17-dione or estrone (other steroid hormone
substrates of AKR1C3) did not alter the protein expression of
AKR1C3 (data not shown).
AKR1C3 expression is upregulated in skin lesions of AD
but not in psoriasis
PGD2 has a significant role in AD-associated inflammation
(Satoh et al., 2006). Our data suggested that keratinocytes
upregulate the expression of AKR1C3 in response to PGD2
and also use this enzyme to metabolize PGD2 to 9a,11b-
PGF2. As the regulation of AKR1C3 in AD may have a role in
controlling the local concentration of this pro-inflammatory
PG, we investigated the expression of AKR1C3 in lesional
and non-lesional skin of AD and psoriasis patients by
immunofluorescence (Figure 5d). AKR1C3 was markedly
upregulated in AD lesions compared with non-lesional
matching controls. In contrast, no differences in AKR1C3
expression were observed in psoriasis lesions compared with
nearby non-lesional skin. Quantification of AKR1C3 expres-
sion by ImageJ confirmed a 2.8±0.4-fold increase in
AKR1C3 expression in AD lesions over matching non-
lesional skin, whereas no change in expression was noted
in psoriasis samples (Figure 5e).
DISCUSSION
AKR1C3 is the only AKR1C family member that also mediates
17b-HSD activity (Penning et al., 2001). Previous work
investigating 17b-HSD activity in human skin sections
localized its peak activity around the basement layer of the
epidermis (Hikima and Maibach, 2007), whereas another
study also suggested a functional role for several AKR1C
isoforms in keratinocyte survival (Marin et al., 2009). The
current work shows that AKR1C3 is differentially expressed in
human epidermis, with the highest expression levels ob-
served in mid-epidermis around the stratum spinosum. Other
work documented multiple AKR1C3-associated 17b-HSD
activities in HaCaT cells, as well as in PHKs. Their data
demonstrated that these enzymatic activities were relatively
low in basal keratinocytes, peaked during early stages of
differentiation, and returned to baseline in terminally
differentiated cultures, suggesting that the expression of
steroid metabolizing enzymes in keratinocytes is differentia-
tion dependent (Gingras et al., 2003). Their work, however,
did not evaluate the protein or transcriptional regulation of
any 17b-HSD enzymes. The current work provides further
evidence that the 17b-HSD enzyme, AKR1C3, is markedly
upregulated in differentiated epidermis and in calcium-
induced PHK differentiation.
AKR1C3 upregulation in differentiated PHK suggests a
differentiation-associated function for this enzyme. To test
this, a specific AKR1C3 siRNA and the specific AKR1C3
inhibitor, 2HFN, were used. 2HFN has been shown to
specifically inhibit recombinant AKR1C3 with an IC50 of
0.3 mM (Skarydova et al., 2009). Our work further demon-
strates the capacity of this flavanoid derivative to inhibit
cellular AKR1C3 ketoreduction activity with an IC50 between
0.5 and 1 mM, suggesting a good bioavailability for this drug
under our experimental conditions.
The current work demonstrates a functional role for
AKR1C3 in gene regulation during keratinocyte differentia-
tion. Of interest is the observation that the interruption of
AKR1C3 expression or activity attenuates K10 expression
while resulting in the upregulation of loricrin. To investigate
whether the upregulation of loricrin was directly due to
AKR1C3 inhibition or the subsequent decrease in K10
expression, we attempted to attenuate K10 expression with
siRNA in PHK during differentiation; however, we were
unable to examine loricrin expression because of cytotoxicity
(data not shown). On the basis of our current data showing
earlier and more profound loricrin expression, it is reasonable
to assume that attenuating AKR1C3 activity during differ-
entiation disrupted this delicate process at its early stages,
which hastened terminal differentiation. Future studies will
be needed to evaluate the regulation of other differentiation-
associated markers such as profilaggrin and involucrin. These
data will provide further insights into whether altered loricrin
expression was a direct outcome of AKR1C3 attenuation
during keratinocyte differentiation, or was it just a part of an
overall hastened terminal differentiation.
As there is no evidence that AKR1C3 directly regulates
gene expression, this action is probably mediated indirectly
by its related PG and/or steroid metabolites, its contribution
to the cellular redox state, or its action in ketoreduction of an
unknown substrate. Keratinocytes synthesize and secrete
PGF2a and express its corresponding receptor FP (Pentland
and Needleman, 1986; Scott et al., 2005). AKR1C3 upregula-
tion during keratinocyte differentiation could result in
increased PGF2a synthesis, which may affect differentiation-
associated gene regulation. However, this mechanism is not
supported by our observations, as the addition of various
doses of PGF2a to AKR1C3 siRNA–treated cells failed to
retrieve normal K10 expression during keratinocyte differ-
entiation (data not shown). AKR1C3 can also convert steroid
hormone precursors to their active form, but as the culture
medium does not contain significant quantities of these
precursors, this mechanism is unlikely. Increased expression
of AKR1C3 during differentiation suggests a requirement for
its enzymatic activity. Our work did not identify a specific
substrate; however, as the ketoreduction activity mediated by
AKR1C3 is also NAD(P)(H) dependent, its increased enzy-
matic activity may affect cellular redox state. This action may
indirectly alter the activity of redox-sensitive transcription
factors that regulate the expression of differentiation-asso-
ciated genes during keratinocyte differentiation (Meyer et al.,
1994; Nakamura et al., 2007). Taken together, AKR1C3 is
likely involved in differentiation-associated gene regulation
www.jidonline.org 1107
A Mantel et al.
AKR1C3 in Normal Epidermis and Atopic Dermatitis
in a PGF2a- and hormone-independent manner. However,
the precise mechanism remains to be definitively resolved by
future work.
Local release of PGD2 is known to have a major role in
regulating T-helper type 2 (Th2) chronic inflammation in AD,
where it mainly serves as a chemoattractant for Th2-
associated immune cells (Iwasaki et al., 2002; Satoh et al.,
2006). Recent work has shown that, in addition to PGD2, its
stable metabolite, 9a,11b-PGF2, mediates the same Th2
inflammatory responses, but with much lower potency
(Sandig et al., 2006). This suggests that both PGD2 and the
accumulation of its stable metabolite 9a,11b-PGF2 may
contribute to inflammation in lesional sites of AD.
Our studies show that PHKs upregulate AKR1C3 specifi-
cally in response to PGD2 and use this enzyme to reduce
PGD2 to 9a,11b-PGF2. In fact, our preliminary data also
suggest that treating PHK with other steroidal substrates of
AKR1C3 (i.e., estrone and D4-androstene-3,17-dione) or with
their corresponding reduced products (17b-estradiol and
testosterone) had no effect on AKR1C3 expression (data not
shown). In addition, treatment with other pro-inflammatory
cytokines such as IL-4, IFN-g, and tumor necrosis factor-a
had no effect on AKR1C3 expression by PHKs (data not
shown). PGD2 is a relatively unstable PG that has been
shown to spontaneously dehydrate to 15-deoxy-D12,14-PGJ2
(15d-PGJ2) in vivo and in vitro (Shibata et al., 2002). 15d-
PGJ2 is an anti-inflammatory lipid that mostly mediates its
actions directly via activation of peroxisome proliferator-
activated receptor g (PPAR-g) and/or inhibition of NF-kB
signaling in immune cells (Forman et al., 1995; Maggi et al.,
2000; Straus et al., 2000; Watanabe et al., 2010). Previous
data have shown that PPAR-g activation attenuates allergen-
induced inflammation in skin and lungs of mice (Ward et al.,
2006; Dahten et al., 2008). This suggests that PPAR-g
activation by 15d-PGJ2 may have a role in suppressing
inflammation in AD patients.
A specific role for AKR1C3 in AD is supported by our
observation that AKR1C3 expression is markedly upregulated
in lesions of this skin condition, but is unchanged in the Th1-
mediated inflammatory lesions of psoriasis (Schlaak et al.,
1994). We propose a model (Figure 6) in which upregulation
of AKR1C3 in AD lesions supports inflammation by directly
causing an increase in 9a,11b-PGF2 synthesis rates and
diverting the spontaneous generation of the potent anti-
inflammatory mediator, 15d-PGJ2. This function of AKR1C3
has been previously implicated in HL-60 cells (Desmond
et al., 2003) and in MCF-7 cells (Byrns et al., 2010). Thus,
AKR1C3 activity and expression in AD lesions could
determine the balance between pro- and anti-inflammatory
PG mediators. This work suggests that inhibition of AKR1C3
may be a potential therapeutic target in AD-associated
inflammation.
MATERIALS AND METHODS
Cell culture
Defatted skin, obtained from breast reduction or panniculectamies,
was placed in 0.25% trypsin in phosphate-buffered saline for 5 hours
at 37 1C and 5% CO2. The epidermis was separated and epidermal
cell suspension placed in T-75 flasks, pre-coated with 1:5 Purecol
(Advanced Biomatrix, San Diego, CA) in keratinocyte growth media
(Invitrogen, Grand Island, NY), and supplemented with 5 ngml1
epidermal growth factor, 20 mgml1 bovine pituitary extract, and
antibiotics. The mediumwas routinely changed every 3–4 days and cells
were passed at B90% confluence. Cells were used at passages 3–6.
Reagents
Monoclonal mouse anti-human AKR1C3 (ab49680), monoclonal
rabbit anti-human keratin 5 (ab52635), and polyclonal rabbit anti-
human b-actin were obtained from Abcam (Cambridge, MA).
Polyclonal rabbit anti-human keratin 10 (PRB-159p-100) and rabbit
anti-human loricrin (PRB-145p) were purchased from Covance
(Emeryville, CA). 20-Hydroxyflavanone, PGE2, PGD2, and 9a,11b-
PGF2 were purchased from Sigma-Aldrich (St Louis, MO) and
dissolved in DMSO as 10mM stocks.
Immunofluorescence
Biopsies were fixed in 10% formalin and then embedded in paraffin.
Sections were deparaffinized in xylene for 10minutes, followed by
graded rehydration in EtOH (100, 95, 85, 70, and 50%) for 5minutes
each. Sections were then incubated in antigen retrieval buffer (10mM
Tris, 1mM EDTA, 0.05% Tween-20, pH 9.0) at 95 1C for 10minutes.
Samples were incubated in 1:50 anti-AKR1C3, 1:2,000 K10, or
1:2,000 keratin 5 antibodies alone or in mixtures as indicated
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Figure 6. A role for aldo-keto reductase 1C3 (AKR1C3) in promoting
inflammation in atopic dermatitis (AD; a suggested model). Pruritus-induced
scratching causes mast cell degranulation and rapid prostaglandin D2
(PGD2) synthesis. PGD2 attracts CRTH2 (chemoattractant receptor-
homologous molecule expressed on Th2 cells)-expressing immune cells,
which in turn can amplify its signaling by synthesizing and secreting more of
this prostaglandin. Keratinocytes respond to high levels of PGD2 by
upregulating AKR1C3 expression and use this enzyme to metabolize
PGD2 to 9a,11b-PGF2, a weaker but very stable pro-inflammatory mediator.
This activity of AKR1C3 competes with the spontaneous conversion of PGD2
to 15-deoxy-D12,14-PGJ2 (15d-PGJ2), an anti-inflammatory/pro-apoptotic
mediator. Upregulation of 9a,11b-PGF2 synthesis along with decreased
formation of 15d-PGJ2, an agonist for peroxisome proliferator-activated
receptor g (PPAR-g) and an inhibitor of NF-kB, potentially situates AKR1C3
as an indirect pro-inflammatory factor in AD.
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overnight at 4 1C. Nonspecific mouse or rabbit IgG controls were
performed in parallel. Samples were then incubated in 1:400
Fluorescein-conjugated goat anti-rabbit IgG, 1:200 Texas Red goat
anti-mouse IgG, or a mixture of both, as required, for 1 hour at room
temperature. Samples were visualized using a fluorescence micro-
scope (Nikon Eclipse E800 equipped with a Spot RT3 camera,
Nikon, Melville, NY). Pictures were obtained using the Spot advan-
ced software (Diagnostic Instruments, Sterling Heights, MI).
ImageJ analysis
ImageJ version 1.440 (NIH, Bethesda, MD) was used. The averages
of the fluorescent pixel intensity of 10 random fields per sample
(rectangular tool) from the site of interest (i.e., the epidermis or a
specific epidermal area) minus the averages of nonspecific
fluorescence (background) were recorded and averaged.
Western blot analysis
Cells were extracted in RIPA buffer containing 1:100 Protease
Inhibitor Cocktail (Santa Cruz Biotechnology, Santa Cruz, CA).
Protein (50mg) was separated on 10% SDS-PAGE and transferred to
nitrocellulose. The membrane was blocked, and then incubated in
the presence of either 1:1,000 anti-AKR1C3, 1:2,000 anti-keratin 10,
1:2,000 anti-loricrin, or 1:4,000 anti-b-actin antibodies at 4 1C
overnight. Matching secondary horseradish peroxidase-conjugated
IgG at 1:2,000 was applied and immunoreactive protein bands
were detected using Western Blot Luminal Reagent (Santa Cruz
Biotechnology).
AKR1C3 siRNA transient transfection
Transfection was performed on cultures at 50% confluence,
according to the manufacturer’s protocol, using 10 nM AKR1C3
Stealth siRNA (oligo ID: HSS112670, Invitrogen) or nonspecific
siRNA (cat# 12935-200, Invitrogen). Transfection medium was
aspirated after 6 hours and replaced by conditioned keratinocyte
growth media as indicated.
Evaluation of AKR1C3 enzymatic activity (PGD2 to 9a,
11b-PGF2 conversion) in PHKs
Cells were cultured in six-well dishes as indicated. Keratinocyte
growth media without supplements (500 ml per well), containing
1mM PGD2, was added to appropriate wells, followed by incubation
at 37 1C for the indicated durations. 9a,11b-PGF2 from each
condition was evaluated in the supernatant by a specific 9a,
11b-PGF2 kit (catalog: 516521, Cayman Chemical, Ann Arbor, MI)
according to manufacturer’s protocol, and results were normalized
to protein content. 9a,11b-PGF2 was detected in 1 mM PGD2-
containing media only after it had been incubated with cells,
whereas no signal was detected in PGD2-containing media alone or
in media exposed to cells that did not contain PGD2 (not shown).
Total RNA isolation and real-time PCR
Total RNA was extracted using Trizol reagent (Invitrogen) and
complementary DNA was synthesized using the SuperScript III
First Strand complementary DNA synthesis kit (Invitrogen). Real-
time PCR primers for AKR1C3 (fwd: 50-GAGAAGTAAAGCTTTGGAG
GTCACA-30, rev: 50-CAACCTGCTCCTCATTATTGTATAAATGA-30)
AKR1C2 (fwd: 50-CCTAAAAGTAAAGCTCTAGAGGCCGT-30, rev:
50-GAAAATGAATAAGATAGAGGTCAACATAG-30) and GAPDH
(fwd: 50-CCACCCATGGCAAATTCC-30, rev: 50-TGGGATTTCCATTG
ATGACAAG-30) were designed using the ABI Primer Express Software
(Applied Biosystems, Foster City, CA). The PCR products were
amplified and detected using SYBR Green in an iCycler iQ real-time
PCR system (Bio-Rad, Hercules, CA). Relative complementary DNA
amounts were calculated on the basis of the threshold cycle (CT)
value and were normalized to the amount of GAPDH by means of
the 2DDCT method.
AD, psoriasis, and normal skin samples
All studies were approved by the Research Subject Review Boards at
the University of Rochester Medical Center and/or by the Research
Subject Review Boards at the Johns Hopkins University. All subjects
gave written informed consent. The diagnosis of AD was made using
the US consensus conference criteria (Eichenfield, 2004). All subjects
underwent a 5-mm punch biopsy from a non-lesional site and an
additional 5mm biopsy from a lesional site. For the expression of
AKR1C3 in normal skin, 6mm biopsies were obtained from the
buttock area of random volunteers who all gave written informed
consent. All experiments were conducted in accordance with
the Declaration of Helsinki Principles (hematoxylin–eosin stains of
psoriasis and AD are shown in Supplementary Figure S1 online).
Statistical analysis
The results are presented as means±SEM. The appropriate t-test was
calculated using Microsoft Excel or GraphPad Prism. A P-value
o0.05 was considered statistically significant.
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